# Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

> **NCT00921804** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 296 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AZD 8529
- **DRUG:** Risperidone
- **DRUG:** Placebo to match AZD8529
- **DRUG:** Placebo to match risperidone

## Key facts

- **NCT ID:** NCT00921804
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2010-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00921804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00921804, "Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients". Retrieved via AI Analytics 2026-09-14 from https://api.ai-analytics.org/clinical/NCT00921804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*